Serum lipoprotein (a) concentrations in a population of 819 non-insulin-dependent diabetic patients

Diabetes and Metabolism

Volumn 22, Issue 5, 1996, Pages 319-323

  Durlach, V ^a,b   Gillery, P ^b   Bertin, E ^a   Taupin, J M ^c   Grulet, H ^a   Gross, A ^a   Leutenegger, M ^a  

^a U 62 Medical Clinic   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c Soissons Hospital Centre   (France)

Author keywords

Body mass index; Complications; Lipoprotein (a); Non insulin dependent diabetes mellitus

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOASSAY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEINS B; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FASTING; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; REFERENCE VALUES; TRIGLYCERIDES;

EID: 0029786177     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Utermann G. The mysteries of lipoprotein (a). Science, 1989, 246, 904-910.
2. Scanu AM, Fless GM. Lipoprotein (a): heterogeneity and biological relevance. J Clin Invest, 1990, 85, 1709-1715.
3. Berg K. Lp(a) lipoprotein: an overview. Chem Phys Lipids, 1992, 66/67, 9-16.
4. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apoliprotein (a) gene accounts for greater than 90 % of the variation in plasma lipoprotein (a) concentrations. J Clin Invest, 1992, 90, 52-60.
5. Gaw A, Boerwinkle E, Cohen JC, Hobbs HH. Comparative analysis of the ap(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for non-commun « null » allele at the apo(a) locus. J Clinic Invest, 1994, 93, 2526-2534.
6. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose tolerance. Diabetes, 1979, 28, 1039-57.
7. Gillery P, Périer C, Stahl A, Delattre J. Recommandations pour le dosage des protéines glyquées par la méthode dite des fructosamines. Ann Biol Clin, 1992, 50, 603-605.
8. Atger V, Wirbel E, Roche D, Apfeblaum M, Burstein M, Girard-Globa A. Distribution of HDL2 and HDL3 in a random population of healthy French males and females - evaluation of a two-step precipitation procedure. Clin Chim Acta, 1990, 189, 111-112.
9. Gillery P, Arthuis P, Cuperlier C, Circaud R. A peak-rate nephelometric assay of serum lipoprotein (a). Clin Chem, 1993, 39, 503-508.
10. Gillery P, Arthuis P. Peak-rate nephelometric assay of lipoprotein (a): one year follow-up [abstract] Clin Chem, 1993, 39, 1122-1123.
11. Haffner SM, Gruber K, Aldrete G, Tuttle KTR. Increased Lp(a) concentrations in renal failure. J Am Soc Nephrol, 1992, 3, 1156-1162.
12. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein (a) as an acute phase protein. Atherosclerosis, 1989, 78, 145-150.
13. Albers JJ, Marcovina SM. Standardization of Lp(a) measurements. Chem Phys Lipids, 1994, 67/68, 257-263.
14. Labeur C, Rosseneu M. Methods for the measurements of lipoprotein (a) in the clinical laboratory. Curr Opin Linidol, 1992, 3, 372-376.
15. Craig WY, Poulin SE, Forster NR, Neveux LM, Wald NJ, Leduc TB. Effect of sample storage on the assay of lipoprotein (a) by commercially available radial immunodiffusion and enzymo-linked immunosorbent assay kits. Clin Chem, 1992, 38, 550-553.
16. Dean JD, Bishop A, Morgan R, Carolan G, Owens DR, Rees A. Lipoprotein (a) in non-insulin-dependent diabetes mellitus. Diab Nutr Metab, 1992, 5, 95-98.
17. Ritter MM, Richter WO, Lyko K, Schwandt P. Lp(a) serum concentrations and metabolic control. Diabetes Care, 1992, 15, 1441-1442.
18. Haffner SM, Morales PA, Gruber MK, Hazuda HP, Stern MP. Lack of association of lipids, lipoproteins and Lp(a) with microalbuminuria in NIDDM. Arterioscler Thromb, 1993, 13, 205-210.
19. Vehlo G, Erlich D, Turpin E et al. Lipoprotein (a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Care, 1993, 16, 742-747.
20. Heller FR, Jamart J, Honore P et al. Serum lipoprotein (a) in patients with diabetes mellitus. Diabetes Care, 1993, 16, 819-823.
21. Bruckert E, Davidoff P, Grimaldi A et al. Increased serum concentrations of lipoprotein (a) in diabetes mellitus and their reduction with glycemic control. JAMA, 1990, 263, 35.
22. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P. Lipoprotein (a) concentrations in diabetes mellitus: relationship to metabolic control. Ann Intern Med, 1992, 117, 41-47.
23. Jenkins AJ, Steele JS, Junus ED, Santamaria JD, Best JD. Plasma apolipoprotein (a) is increased in type II (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia, 1992, 35, 1055-1059.
24. Ruiz J, Thillet J, Huby T et al. Association of elevated lipoprotein (a) concentrations and coronary heart disease in NIDDM patients. Relationship with apolipoprotein (a) phenotypes. Diabetologia, 1994, 37, 585-591.
25. Durlach V, Gillery P, Grulet H et al. Relations entre lipoprotéine (a) et fonction rénale chez les diabétiques: à propos de 1154 patients [abstract]. Diabete Metab, 1994, 20, 21A.
26. Niskanen L, Mykkänen L, Karonen SL, Uusitupa M. Apoprotein (a) concentrations in relation to coronary heart disease and risk factors in Type II (non-insulin-dependent diabetes). Cardiovasc Risk Factors, 1993, 13, 205-210.
27. Hervio L, Durlach V, Girard-Globa A, Angles-Cano E. Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein (a) on fibrinolysis. Biochemistry, 1995, 34, 13353-13358.
28. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation, 1992, 86, 475-482.
29. Dieplinger H, Lackner C, Kronenberg F et al. Elevated plasma concentrations of lipoprotein (a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein (a). J Clin Invest, 1993, 91, 397-401.
30. Guillausseau PJ, Peynet J, Chanson P et al. Lipoprotein (a) in diabetic patients with and without chronic renal failure. Diabetes Care, 1992, 15, 976-979.
31. Nielsen FS, Voldsgaard Al., Gall MA et al. Apolipoprotein (a) and cardiovascular disease in Type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. Diabetologia, 1993, 36, 438-444.
32. Gall MA, Rossing P, Hommel E et al. Apoplipoprotein (a) in insulin-dependent diabetic patients with and without nephropathy. Scand J Clin Lab Invest, 1992, 52, 513-522.
33. Jenkins AJ, Steele JS, Janus ED, Best JD. Increased plasma apolipoprotein (a) concentrations in IDDM patients with microalbuminuria. Diabetes, 1991, 40, 787-790.
34. Kapelrud H, Bangstad HJ, Jorgensen KD, Berg K, Hansen KF. Serum Lp(a) lipoprotein concentrations in insulin-dependent diabetic patients with microalbuminuria. Br Med J, 1991, 303, 675-678.
35. Tagegoshi T, Haba T, Hirai JK et al. Alterations of lipoprotein (a) in patients with diabetic nephropathy. Atherosclerosis, 1990, 83, 99-100.
36. Sidhu M, Crook D, Godsland IF, Walton C, Wynn V, Oliver MF. Inverse relationship between serum Lp(a) concentrations and first phase insulin secretion. Diabetes, 1992, 41, 1341-1345.
37. Sundell JB, Nilsson TK, Hallmans G, Hellsten G, Dahlen GH. Interrelationship between plasma concentrations of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a) and established cardiovascular risk factor in a North Swedish population. Atherosclerosis, 1989, 80, 9-16.
38. Krempler F, Kostner G, Bolzano K, Sandhofer F. Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein B. Biochim Biophys Acta, 1979, 575, 63-70.
39. Wilkinson J, Munro KH, Higgins JA. Apolipoprotein (a) is not associated with apolipoprotein B in human liver. J Lipid Res, 1994, 35, 1896-1901.
40. Conn JS, Lam CWK, Sullivan Dr, Hensley WJ. Plasma lipoprotein distribution of apolipoprotein (a) in the fed and fasted states. Atherosclerosis, 1991, 90, 59-66.
41. Scanu AM, Pfaffinger D, Edelstein C. Postprandial Lp(a): identification of a triglyceride-rich particle containing apo E. Chem Phys Lipids, 1994, 67/68, 193-198.
42. Pfaffinger D, Schuelke J, Kim C, Fless GM, Scanu AM. Relationship between apo (a) isoforms and Lp(a) density in subjects with different apo (a) phenotype: a study before and after a fatty meal. J Lipid Res, 1991, 32, 679-683.
43. Bersot TP, Innerarity TL, Pitas RE, Rall SC, Weisgraber KH, Mahley RW. Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein (a) and that cause lipid accumulation in macrophages. J Clin Invest, 1986, 77, 622-630.
44. Ritter MM, Geiss HC, Richter WO, Schwandt P. Lipoprotein (a) concentrations and phenotypes in controls and patients with hypercholesterolemia or hypertriglyceridemia. Metabolism, 1994, 43, 572-578.
45. Corsetti JP, Sterry JA, Sparrks JD, Sparks CE, Weintraub W. Effect of weight loss on serum Lp(a) concentrations in obese population. Clin Chem, 1991, 37, 1191-1195.
46. Muls E, Kempen K, Cobbaert C, Saris W. The effects of weight loss and apoprotein E polymorphism on serum lipids, apoprotein Ai, and B, and lipoprotein (a). Int J Obesity, 1993, 17, 711-716.
47. Corcuff JB, Navaranne A, Dumon MF et al. Lipoprotéine (a) chez l'obèse. Ann Endocrinol, 1995, 56, 225-229.
48. Sonnichsen AC, Richter WO, Schwandt P. Reduction of lipoprotein (a) by weight loss. Int J Obesity, 1990, 14, 487-494.